For improved treatment efficacy with no or few adverse effects and higher patient compliance, novel delivery techniques with selective dispersion are required. The biodegradable and biocompatible polymers hyaluronic acid (HA), polyethylene glycol (PEG), and polycaprolactone (PCL) were used to create paclitaxel-loaded nanoparticles. The development and characterisation of a Paclitaxel-loaded HA-PEG-PCL polymeric nanoparticulate drug delivery system were the goals of the current study work in order to increase the therapeutic efficacy and targeted Paclitaxel distribution. The copolymers were chemically created, and IR spectroscopies were used to identify them. Transmission electron microscopy, particle size, percentage of drug entrapment, cell viability studies, stability, and in vitro drug release profile were used to describe the nanoparticles' structure and morphology. To determine whether PTX was crystalline or amorphous inside the polymer matrix, experiments using differential scanning calorimetry and X-ray diffraction were also carried out. Zeta potentials for blank NPs and PTX-HA-PEG-PCL NPs were respectively -15.4±1.23 mV and -18±2.35 mV. In 144 hours, PTX-HA-PEG-PCL NPs demonstrated a 58.08±3.8 release of PTX at pH 7.4. Because HA functions as a ligand for the CD44 receptors that are over expressed on HT29 cells, the PTX-HA-PEG-PCL NPs demonstrated noticeably more cytotoxicity as a result of better formulation internalization. The proposed nanotechnology’s-controlled drug release behavior showed its potential for colon cancer cell lines.

: Biodegradable polymer, Colon cancer, Paclitaxel, Hyaluronic acid, Nanoparticles, Targeted drug delivery